Filing Details
- Accession Number:
- 0001013594-25-000763
- Form Type:
- 13D Filing
- Publication Date:
- 2025-06-16 20:00:00
- Filed By:
- Paulson & Co
- Company:
- Bausch Health Companies Inc. (NYSE:BHC)
- Filing Date:
- 2025-06-17
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| PAULSON & CO. INC. | 32,791,702 | 0 | 32,791,702 | 0 | 32,791,702 | 8.9% |
Filing
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 4)
|
Bausch Health Companies Inc. (Name of Issuer) |
Common Shares, no par value (Title of Class of Securities) |
071734107 (CUSIP Number) |
Kelly Zelezen, Esq Kelly Zelezen, Esq., 500 Fifth Avenue New York, NY, 10110 212-986-6000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
06/13/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 071734107 |
| 1 |
Name of reporting person
PAULSON & CO. INC. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
32,791,702.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
8.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
Items #7, 9, and 11: See Note 1 to Item 5 below.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Shares, no par value | |
| (b) | Name of Issuer:
Bausch Health Companies Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
2150 ST. ELZEAR BLVD. WEST, LAVAL, QUEBEC,
QUEBEC, CANADA
, H7L 4A8. | |
Item 1 Comment:
The following constitutes Amendment No. 4 to the Schedule 13D filed by the undersigned ("Amendment No. 4"). This Amendment No. 4 amends the Schedule 13D as specifically set forth herein. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | The aggregate percentage of Common Shares reported owned by the Reporting Person is based upon approximately 367,933,897 Common Shares outstanding as of February 14, 2025, which is the total number of Common Shares outstanding as disclosed on the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 20, 2025. As of the date hereof, the Reporting Person may be deemed to have beneficially owned approximately 8.9% of the outstanding Common Shares. | |
| (b) | Number of Common Shares as to which Paulson has:
(i) Sole power to vote or direct the vote: 32,791,702 (see Note 1).
(ii) Shared power to vote or direct the vote: 0
(iii) Sole power to dispose or direct the disposition: 32,791,702 (see Note 1).
(iv) Shared power to dispose or direct the disposition: 0 | |
| (c) | The transactions effected by the Reporting Person during the past 60 days are set forth on Exhibit 1 attached hereto. | |
| (d) | See Note 1. | |
| (e) | Not applicable.
Note 1: Paulson furnishes investment advice to and manages the Funds. In its role as investment advisor, or manager, as the case may be, Paulson possesses voting and investment power over the securities of the Issuer described in this Schedule 13D that are owned by the Funds. The pecuniary interest of all securities reported in this Schedule 13D is owned by the Funds. Except for the purposes of determining beneficial ownership under Section 13(d) of the Securities Exchange Act of 1934, as amended, Paulson disclaims beneficial ownership of all securities reported in this Schedule 13D.
For reporting purposes, the aggregate amount of Common Shares deemed to be beneficially owned by the Reporting Person is calculated based on an aggregate 32,791,702 Common Shares held by the Reporting Person as of the date hereof. | |
| Item 7. | Material to be Filed as Exhibits. | |
EXhibit 1: Transactions in Securities | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|